{"groups":[{"description":"Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuestionnaire Administration: Ancillary studies","id":"FG000","title":"Treatment (Ixazomib Citrate, Lenalidomide)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"22"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Malignancy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"64"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"45"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with the following conditions were excluded from the study: grade 2 or higher peripheral neuropathy; major surgery or radiotherapy within 14 days of starting on the study; central nervous system involvement; treatment with modulators of CYP1A2 and CYP3A enzyme activity; and cardiovascular complications or ongoing systemic infections.","recruitmentDetails":"64 participants were enrolled in the study between December 3, 2012 and May 13, 2015"}